Published in FEBS Lett on April 09, 1991
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol (1995) 3.80
Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol (1994) 3.70
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol (2002) 1.71
Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. J Virol (1994) 1.70
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol (2004) 1.65
Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol (2004) 1.52
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J (2005) 1.46
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol (2003) 1.37
Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J Virol (1994) 1.30
Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol (2005) 1.28
Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J Virol (2007) 1.18
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol (2006) 1.15
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol (2011) 1.14
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol (2006) 1.10
The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases. J Virol (2003) 1.06
Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci (1993) 0.99
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J Virol (2003) 0.97
A look inside HIV resistance through retroviral protease interaction maps. PLoS Comput Biol (2007) 0.96
Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol (2000) 0.94
Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem (2012) 0.94
Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease. Protein Sci (2009) 0.93
Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease. J Virol (2005) 0.93
Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci U S A (1997) 0.92
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J Virol (2005) 0.91
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci (2012) 0.91
Gag-Pol processing during HIV-1 virion maturation: a systems biology approach. PLoS Comput Biol (2013) 0.89
HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J Mol Biol (2007) 0.88
A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV-infected cells. Nucleic Acids Res (2010) 0.86
Comparative studies on retroviral proteases: substrate specificity. Viruses (2010) 0.85
The substrate specificity of Metarhizium anisopliae and Bos taurus carboxypeptidases A: insights into their use as tools for the removal of affinity tags. Protein Expr Purif (2010) 0.83
Identification of structural mechanisms of HIV-1 protease specificity using computational peptide docking: implications for drug resistance. Structure (2009) 0.83
Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Sci (2012) 0.82
Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain. J Virol (2015) 0.82
Understanding HIV-1 protease autoprocessing for novel therapeutic development. Future Med Chem (2013) 0.79
Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway. Biochem J (1999) 0.79
Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease. Biochemistry (2013) 0.78
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution. Evol Appl (2015) 0.77
A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. J Mol Biol (2015) 0.76
A modular system to evaluate the efficacy of protease inhibitors against HIV-2. PLoS One (2014) 0.76
In silico prediction of mutant HIV-1 proteases cleaving a target sequence. PLoS One (2014) 0.76
Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol (2015) 0.75
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 10.53
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng (2001) 5.71
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci U S A (1985) 5.36
Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual post-translational proteins modification. Proc Natl Acad Sci U S A (1983) 5.12
Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology (1985) 4.65
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell (1998) 4.52
Human immunodeficiency viruses. Science (1986) 4.34
In vivo modification of retroviral gag gene-encoded polyproteins by myristic acid. J Virol (1983) 4.09
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Amino terminal myristylation of the protein kinase p60src, a retroviral transforming protein. Science (1985) 3.97
Group-specific antigen expression during embryogenesis of the genome of the C-type RNA tumor virus: implications for ontogenesis and oncogenesis. Proc Natl Acad Sci U S A (1970) 3.71
Thin-layer chromatography of sub-nanomole amounts of phenylthiohydantoin (PTH) amino acids on polyamide sheets. Anal Biochem (1973) 3.66
Interactions of retroviral structural proteins with single-stranded nucleic acids. J Biol Chem (1987) 3.62
Nucleotide sequence of the p21 transforming protein of Harvey murine sarcoma virus. Science (1982) 3.55
Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science (1985) 3.27
Primary structure of the low molecular weight nucleic acid-binding proteins of murine leukemia viruses. J Biol Chem (1981) 3.21
Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J Immunol (1983) 3.10
Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15. AIDS Res Hum Retroviruses (1987) 3.03
Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins. J Virol (1987) 3.02
Purified maturation promoting factor phosphorylates pp60c-src at the sites phosphorylated during fibroblast mitosis. Cell (1989) 3.01
Fatty acylation of proteins. Annu Rev Cell Biol (1988) 2.92
Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products. J Virol (1984) 2.91
Identification of a precursor in the biosynthesis of the p21 transforming protein of harvey murine sarcoma virus. J Virol (1982) 2.89
Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus. Proc Natl Acad Sci U S A (1978) 2.87
Proteins of the murine C-type RNA tumour viruses: isolation of a group-specific antigen by isoelectric focusing. J Gen Virol (1970) 2.80
C-type virus released from cultured human rhabdomyosarcoma cells. Nat New Biol (1972) 2.78
Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses. J Virol (1986) 2.77
Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne). J Virol (1988) 2.76
Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2. Science (1988) 2.76
Coexistence of intraspecies and interspecies specific antigenic determinants on the major structural polypeptide of mammalian C-type viruses. Nat New Biol (1971) 2.70
Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem (1993) 2.70
Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol (1986) 2.65
Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses. J Biol Chem (1982) 2.59
A micromethod for complete removal of dodecyl sulfate from proteins by ion-pair extraction. Anal Biochem (1979) 2.57
Primary structure analysis of the major internal protein p24 of human type C T-cell leukemia virus. Proc Natl Acad Sci U S A (1982) 2.57
Translational readthrough of an amber termination codon during synthesis of feline leukemia virus protease. J Virol (1985) 2.53
The group-specific antigen and other structural proteins of hamster and mouse C-type viruses. Virology (1971) 2.46
Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron (1994) 2.44
Purification and N-terminal amino acid sequence comparisons of structural proteins from retrovirus-D/Washington and Mason-Pfizer monkey virus. J Virol (1985) 2.43
Separation of amino acid phenylthiohydantoins by high-performance liquid chromatography on phenylalkyl support. Anal Biochem (1980) 2.30
HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro. Proc Natl Acad Sci U S A (1996) 2.30
Bovine leukemia virus protease: purification, chemical analysis, and in vitro processing of gag precursor polyproteins. J Virol (1986) 2.28
Myristylation of gag-onc fusion proteins in mammalian transforming retroviruses. Virology (1984) 2.22
Species-specific and interspecific antigenic determinants associated with the structural protein of feline C-type virus. Proc Natl Acad Sci U S A (1971) 2.20
Structural characterization of the avian retrovirus reverse transcriptase and endonuclease domains. J Biol Chem (1985) 2.18
Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene. J Virol (1979) 2.16
Capsid protein VP4 of poliovirus is N-myristoylated. Proc Natl Acad Sci U S A (1987) 2.12
Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. Proc Natl Acad Sci U S A (1984) 2.12
Primary structure and processing of gag and env gene products of human T-cell leukemia viruses HTLV-ICR and HTLV-IATK. Curr Top Microbiol Immunol (1985) 2.09
Amino acid sequence analysis of reverse transcriptase subunits from avian myeloblastosis virus. J Virol (1980) 2.09
Translational suppression in retroviral gene expression. Adv Virus Res (1992) 1.93
The where, what and how of ribosomal frameshifting in retroviral protein synthesis. Trends Biochem Sci (1990) 1.92
Purification and immunological characterization of the major internal protein of the RD-114 virus. Proc Natl Acad Sci U S A (1972) 1.92
Complete amino acid sequence of the basic nucleic acid binding protein of feline leukemia virus. Virology (1984) 1.86
Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science (1992) 1.85
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract. J Virol (1996) 1.83
Characterization of mouse mammary tumor virus gag-pro gene products and the ribosomal frameshift site by protein sequencing. Proc Natl Acad Sci U S A (1987) 1.81
Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus. J Virol (1990) 1.75
Murine leukemia virus gag polyproteins: the peptide chain unique to Pr80 is located at the amino terminus. Virology (1978) 1.73
Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem (2001) 1.68
Purification and primary structure of a polypeptide with multiplication-stimulating activity from rat liver cell cultures. Homology with human insulin-like growth factor II. J Biol Chem (1981) 1.65
Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A (1988) 1.64
Detection of the myristylated gag-raf transforming protein with raf-specific antipeptide sera. Virology (1985) 1.64
Amino-terminal amino acid sequence and carboxyl-terminal analysis of Rauscher murine leukemia virus glycoproteins. Virology (1978) 1.59
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem (1994) 1.57